Zevit vs. Evit: Delhi High Court Establishes Precedence on Trademark Deceptive Similarity

Introduction

The case of Remidex Pharma Private Limited v. Savita Pharmaceuticals P. Ltd adjudicated by the Delhi High Court on July 3, 2006, marks a significant precedent in the realm of trademark law in India. This case revolves around the alleged trademark infringement where the plaintiff, Remidex Pharma, contends that the defendant, Savita Pharmaceuticals, has used a deceptively similar mark, "EVIT," infringing upon the plaintiff's registered trademark "ZEVIT."

The central issue pertains to whether "EVIT" is deceptively similar to "ZEVIT" to the extent that it could cause confusion among consumers, thereby constituting trademark infringement under the Trademark Act, 1999.

Summary of the Judgment

The court examined the claims brought forth by the plaintiff, who holds the registered trademark "ZEVIT," alleging that the defendant's use of "EVIT" for its vitamin E capsules infringes upon their trademark. The plaintiff argued that "ZEVIT" is an invented term with high distinctiveness, whereas the defendant contended that "EVIT" is a generic term in the pharmaceutical trade, combining "E" for Vitamin E and "VIT" as a common suffix for vitamin formulations.

After thorough analysis, the Delhi High Court upheld the interim injunction previously granted in favor of the plaintiff, confirming that "EVIT" is deceptively similar to "ZEVIT." The court emphasized the phonetic similarity between the prefixes "ZE" and "E," alongside their identical suffix "VIT." Consequently, the court concluded that the likelihood of consumer confusion substantiates the claim of trademark infringement.

Analysis

Precedents Cited

The judgment extensively references several landmark cases to underpin its reasoning:

• National Bell Co. v. Metal Goods Manufacturing Co. (P.) Ltd., AIR 1971 SC 898
• American Home Products Corporation v. Mac Laboratories Pvt. Ltd & Anr., AIR 1986 SC 137
• Durga Dutt Sharma v. N.P Laboratories, AIR 1965 SC 980
• Avis International Ltd v. Avi Footwear Industries & Anr., AIR 1991 Delhi 22
• F. Hoffimann-La Roche and Co. Ltd. v. Geoffrey Manners and Co. Pvt. Ltd., AIR 1970 SC 2062

Of particular significance is the Supreme Court's decision in F. Hoffimann-La Roche and Co. Ltd. v. Geoffrey Manners and Co. Pvt. Ltd. This case examined the deceptive similarity between "DROPOVIT" and "PROTOVIT," establishing that trademarks must be assessed as whole words with emphasis on uncommon elements rather than generic suffixes.

Legal Reasoning

The court's legal reasoning hinges on Section 29 of the Trademarks Act, 1999, which outlines what constitutes infringement. The principle is that if a mark’s overall impression is likely to be confused with a registered mark, it constitutes infringement. The judgment delineates the following key points:

• Trademark as a Whole: Marks must be compared in their entirety, considering both common and uncommon elements.
• Emphasis on Uncommon Elements: Greater weight is given to unique elements of the marks rather than generic suffixes like "VIT."
• Phonetic and Visual Similarity: The similarity in pronunciation and appearance between "ZE" and "E" was crucial in the court’s decision.
• Likelihood of Confusion: The court concluded that the similarity could lead to consumer confusion, thus supporting the plaintiff's claim.

The court rejected the defendant's argument that "VIT" is generic and should be disregarded in the comparison. Instead, it affirmed that the entire mark, including the suffix, needs to be evaluated to ascertain deceptive similarity.

Impact

This judgment reinforces the importance of considering both phonetic and visual aspects of trademarks in infringement cases. It underscores that even if a portion of the mark is generic, the overall similarity must be assessed holistically. The decision serves as a precedent for future cases involving trademark disputes, particularly in the pharmaceutical industry where common suffixes are prevalent.

Moreover, it clarifies that generic suffixes cannot be used as a shield to obscure deceptive similarity, thereby empowering trademark holders to protect their brands against infringing marks that might superficially appear divergent.

Complex Concepts Simplified

Understanding trademark infringement can be complex, but this judgment highlights key concepts in a clear manner:

• Interim Injunction: A temporary court order that restrains a party from taking certain actions until the final judgment is made.
• Deceptive Similarity: When a trademark is so similar to another that consumers might be misled into believing they are associated with the same source.
• Prima Facie Evidence: Evidence that is sufficient to establish a fact or a case unless disproved.
• Likelihood of Confusion: The probability that consumers might be confused about the origin of a product or service due to similar trademarks.

In essence, the court made it clear that trademark protection is not just about the uniqueness of the entire mark but also about how consumers perceive the similarity between different marks in the marketplace.

Conclusion

The Delhi High Court's decision in Remidex Pharma Private Limited v. Savita Pharmaceuticals P. Ltd serves as a pivotal reference in trademark law, particularly concerning deceptive similarity. By affirming that "EVIT" is deceptively similar to the registered "ZEVIT," the court has reinforced the principle that trademarks must be evaluated holistically, considering both common and unique elements.

This judgment emphasizes that generic suffixes do not absolve parties from infringing upon distinct trademarks and that the overall impression created by a mark plays a crucial role in determining infringement. Consequently, businesses must exercise caution in selecting trademarks to ensure they do not inadvertently infringe upon existing brands, thereby safeguarding their market identity and consumer trust.

Overall, this case enhances the legal framework governing trademark protection in India, providing clear guidelines for evaluating similarity and reinforcing the rights of trademark proprietors to prevent unauthorized use of their marks.